COVID-19 Related Resources


To help guide the community, DTRF reached out to our Medical Advisory Board member, Rashmi Chugh, MD, medical oncologist and researcher at the University of Michigan Health System, for her professional opinion on desmoid tumor patients and the COVID-19 vaccines.
Dr. Chugh’s full statement is as follows:
“I urge the desmoid tumor community to protect themselves and their loved ones with the COVID-19 vaccine. Based on available scientific evidence, there is no reason to suspect the COVID-19 vaccine would promote desmoid tumor growth or recurrence. The vaccine has been given to thousands of cancer patients safely, and the risks of contracting COVID-19 remains much, much higher than the risk of the vaccine. Please consider obtaining the vaccine and continue social distancing, wearing masks, and hand-washing so we can stay safe and continue the fight against desmoids together.”
Dr. Chugh’s research focus is on the development of new therapies in the management of sarcoma and desmoid tumors, conducting phase I clinical trials of novel therapies alone or in combination with standard cytotoxic therapy or targeted agents.
The DTRF supports Dr. Chugh’s assessment and we encourage patients and caregivers to bring any questions related to vaccines to your medical team or specialist.

Resources from The National Organization for Rare Disorders (NORD)

The National Organization for Rare Disorders (NORD) recently opened 2 COVID-19 Relief programs.
The COVID-19 Premium & Medical Relief Program
A second program, the COVID-19 Critical Relief Program, provides support to rare disease patients and families facing financial challenges in affording critical, non-medical expenses.
Through this new program, NORD will provide financial assistance to eligible patients impacted by the COVID-19 pandemic, with financial assistance for unexpected or emergency, essential expenses such as:
Assistance may only be provided in one NORD COVID-19 Assistance Program: Critical Needs OR Premium & Limited Medical Assistance.
Eligibility requirements for both NORD programs:
Those who wish to be considered for eligibility need to reach out to NORD at 203.242.0497 or and provide the following:
It may be several days before NORD is able to reach out but please be assured that they will contact each individual seeking assistance through this program.

Resources from The Desmoid Tumor Research Foundation

Resources from The Sarcoma Foundation of America

The Sarcoma Foundation of America hosts a panel of sarcoma specialists discussing sarcoma and coronavirus.

U.S. Centers for Disease Control

To access the most recent information on COVID-19 (aka: coronavirus), we recommend referencing the following websites:

The World Health Organization (WHO)